1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,350 | 6,350 | 26.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | XFRA AUFHEBUNG VON AMTS WEGEN IN US00704R1095, CA57778R1001, US5949728530, CA83179X1087 | 582 | Xetra Newsboard | Folgende Geschaefte in der ISIN US00704R1095, Wertpapier-Name: ADLAI NORTYE LTD. SP.ADR, wurden von Amts wegen aufgehoben:Folgende Geschaefte in der ISIN CA57778R1001, Wertpapier-Name: MAX POWER MINING... ► Artikel lesen | |
| 13.02. | H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target | 1 | Investing.com | ||
| ADLAI NORTYE Aktie jetzt für 0€ handeln | |||||
| 12.02. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.02. | Adlai Nortye Ltd.: Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations | 181 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 03.02. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.02. | Adlai Nortye Leaps On Stock Deal | 3 | Baystreet.ca | ||
| 03.02. | Adlai Nortye jumps 25%, raises $140M via private placement | 2 | Seeking Alpha | ||
| 03.02. | Adlai Nortye Ltd.: Adlai Nortye Announces $140.0 Million Private Placement Equity Financing | 191 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 29.01. | Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating | 8 | Investing.com | ||
| 29.12.25 | Adlai Nortye Stock Rises On Exclusive AN9025 China Licensing Deal With ASK Pharm | 2 | RTTNews | ||
| 29.12.25 | Adlai Nortye vergibt Lizenz für Krebsmedikament in 230-Millionen-Dollar-Deal an ASK Pharm | 13 | Investing.com Deutsch | ||
| 29.12.25 | Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal | 3 | Investing.com | ||
| 29.12.25 | Adlai Nortye Ltd.: Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China | 462 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 29.12.25 | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.12.25 | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.10.25 | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,724 | +1,47 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,990 | -2,36 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,041 | +0,79 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,610 | -1,85 % | SRPT Stock Surges on Promising Early Results From siRNA Programs | ||
| EXACT SCIENCES | 89,28 | 0,00 % | XFRA EXK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXACT SCIEN. DL-... ► Artikel lesen | |
| BASILEA | 56,50 | -1,40 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea startet erste klinische Studie am Menschen für neuartiges Antibiotikum BAL2420 | Allschwil, 23. März 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 7,914 | +2,20 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 99,32 | +0,06 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 13,440 | -1,90 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CODEXIS | 1,444 | +0,63 % | Analyst Sentiment Unchanged After Codexis (CDXS) Earnings | ||
| ORUKA THERAPEUTICS | 39,800 | +1,02 % | Piper Sandler bestätigt "Overweight"-Rating für Oruka Therapeutics | ||
| MACROGENICS | 2,750 | +0,81 % | MacroGenics, Inc.: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures | Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030... ► Artikel lesen | |
| OMEROS | 9,000 | +0,50 % | Omeros Corporation: Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22,... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,075 | -3,04 % | Spero Therapeutics: EPS übertrifft Schätzungen um 0,73 $ - Umsatz besser als erwartet | ||
| KALVISTA PHARMACEUTICALS | 16,300 | -0,61 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update | $49.1 million global net product revenue of EKTERLY (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February... ► Artikel lesen |
ADLAI NORTYE LTD ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,200 (-3,45 %) liegt der Kurs bei 5,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADLAI NORTYE LTD ADR finden Sie auf Wallstreet Online.